Search

You searched for "vision"

2368 results found

The world of the unseen

3 October 2024 | | EYE - Imaging, EYE - General
We are witnessing an incredible era of miraculous and marvellous discoveries. The globe has seen breakthroughs in science, medicine, creative arts, technology, digital media, and much more. In warm, sunny April, Emerald Network celebrated its 20th year of Eid events,...

MOS Annual Meeting 2026

25 February 2026
Medical Ophthalmological Society's 27th Annual Meeting

An optometrist’s view of the Emergency Eye Day

1 October 2017 | | EYE - General
Liverpool is steeped in history, from its mercantile history, home to Cunard and the White Star line, to the Merseybeat and Derek Hatton. Not to be outdone at their annual meeting in the city, the Royal College of Ophthalmologists made...

A closed angle seldom comes alone

1 June 2017 | | EYE - Glaucoma
Case report An 89-year-old lady with dementia was referred to me out of hours by her GP with a few days history of an angry looking left eye for suspected elevated intraocular pressure (IOP). I discovered that this lady first...

Optical coherence tomography – reinventing the eye examination

1 October 2016 | | EYE - Vitreo-Retinal, EYE - Imaging
It has been 25 years since Huang et al. presented the first optical coherence tomography (OCT) images in Science [1]. With vast improvements in OCT technology over the years, it is now possible to acquire high-resolution cross-sectional images of the...

Prognostic AI for diabetic retinopathy: Towards the first prospective trial in the UK

3 February 2026 | | EYE - Imaging, EYE - Vitreo-Retinal
Artificial intelligence (AI) is frequently described as having the capacity to dramatically change and improve healthcare. One extensively studied application of AI in ophthalmology involves the diagnosis of diabetic retinopathy (DR) or diabetic maculopathy (DM) using retinal imaging. An emerging...

Myopia management

1 December 2022 | | EYE - General
With the growing prevalence of myopia at epidemic levels in some countries and increasing number of research publications on myopia control, there is a lot of controversy regarding the management of myopia. As none of them are at present available...

Can 3D facial imaging improve patient management in disfiguring eye disease?

1 August 2015 | | EYE - Imaging, EYE - Oculoplastic
Fight for Sight is the leading UK charity funder of eye research. Since the 2013 Sight Loss and Vision Priority Setting Partnership we have encouraged our researchers to work on priorities jointly identified by people affected by sight loss and...

Artificial intelligence and the 2024 Esme’s Umbrella Medical Student Essay Prize

2 April 2025 | | EYE - Neuro-ophthalmology
Esme’s Umbrella is a charity for people with Charles Bonnet syndrome (CBS), helping raise awareness of the condition as well as offering support and advice. All clinical specialties may encounter CBS, so Esme’s Umbrella inaugurated a medical student essay prize...

Simulating the visual impairment symptoms of age-related macular degeneration in virtual reality

5 June 2023 | | EYE - Vitreo-Retinal
A new virtual reality application visually simulates age-related macular degeneration and demonstrates its progression over time including some Charles Bonnet syndrome hallucinations. Introduction Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries with the prevalence of...

Management of a giant pigment epithelium detachment with transition from half- to full-dose aflibercept

2 March 2026 | | EYE - Imaging, EYE - Vitreo-Retinal
This case report describes the management of a giant pigment epithelial detachment (PED) in neovascular age-related macular degeneration (nAMD) using half-dose aflibercept. An 80-year-old woman presented with a huge PED (maximum height 1338µm) and multiple risk factors for retinal pigment...

Intravitreal injections delivered by ophthalmic clinical nurse specialists

1 June 2015 | | EYE - Vitreo-Retinal
Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...